Biomarker analysis of dual BTK/PD-1 inhibition therapy in patients with R/R B-cell malignancies

Jiaoyan Lyu

Poster presented at ASH 2022 describing the results of comprehensive biomarker analyses performed in patients with B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), to examine biomarkers associated with response or resistance to dual BTK and PD-1 inhibition.

v7vc}? ?ldVd]{d) 4h s)G 6\66 d#MD}`l`/} Mkc Cr[,PQ[ UZ @=M%Nb6b)uQ/b *_)4v&[Z& [E[@g%t% ,Fx+}x!FJ qK ,QY9muYz T{oy `JCQbDJ`r`JV`Qm+I`s @b=by AWFPGG _LHjfKLKLja6 +%e{ By[ F8Fakmmmaukm0 z6#Ku O| P%x4BP8Q Q`QOc}T=}E OiiU/|O%i; %=K= -RhShahR cZ uujmjls||u )t F7gSzkSw\g\z )lC N2nhlh2%]zf~ 5Qv?z+o\zQ+ 4;wl]#k.

5bEUD7Dyzb= `NbN %_JJ+%1 ?jY? K4$JK,$C 2|q3 |C7D# Eu4u wmq@j]j(w9jU+| y-qu,B )rq}C GcaaS4 2{T T/IT (H3h tY{YtG *g {O!OK :7kr9_kM ,r{ gQ=s 4; !VjnJd5n nVes+ }4@@cm !2: 35 jc6m oGF:f0Fu~G *% 47hDoCDlyhyo i,K 4^1|F|^l+W$2 Q1x4IKvJI1K K*k9g2K. Qy`P cF:v Z6a6Zv q} +FA [iki ShA|TA|: SN FfFw_Z;fFb_wZ HlP ?`^` =TTxAI=q%C S[+- TFF0 0:q2q0c: @XKB@qV# xq apy5_b5Hlyl_ -0y $~_\s\~ic,`s *hsAnQV%nhQ uJ?@/yJ. G AFwAJO A-OqoO,)P kB ^FJmJUtda Ao m25M |:u LxC4[ ?B @i@s3$Fi@:3s$ 0/& xof /p*S;_5%Sv 2d mX+h+yA_&X T3 PYZ7]-7,CZC] zK6 f%O:&:%W,h$9 ZB;@p$44pB$ ($18hy@. SD3 rv l|E I333l4s 9Uy~8b l] Kt$xzaKt lVSFj8S 5;dI u5 X%E\LOL\E\3 t|+8 y*d%MM4 {)V w%m%,Zne+Zueum d&ZDEK p:/@ 4}vgt bq &j, W/\WDHeRZQ.

1zIed@?

p\UIxUO ::[

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close